Aptinyx Inc

Aptinyx — Technical Presentation (October 2020)

24 slides from Aptinyx's technical presentation, Oct 20, 2020

  1. Slide 1: Phase 2 PTSD Study Top-Line Results

    Phase 2 PTSD Study Top - Line Results October 20, 2020

  2. Slide 2: This presentation has been prepared by Aptinyx Inc. (“we,” ”us,” “our,” “Aptinyx,” or the

    This presentation has been prepared by Aptinyx Inc. (“we,” ”us,” “our,” “Aptinyx,” or the “Company”) and is made for informat ion al purposes only and does not constitute an offer to sell or a solicitation of an offer to buy securities, nor shall there be any sale of any securitie s i n any state or

  3. Slide 3: PTSD

    PTSD October 20, 2020 3 both approved ~ 20+ years ago ONLY 2 APPROVED THERAPIES with an estimated lifetime prevalence of 6.8% people suffering from PTSD in the U.S. ~ 8.5 MILLION Numerous causes of PTSD Car accidents Criminal assault War combat Natural disaster Sexual trauma 50 - 66 % also battle si

  4. Slide 4: Differentiated Approach to Targeting PTSD

    ANTIDEPRESSANTS – Mood ANXIOLYTICS – Severe anxiety - related complications HYPNOTICS – Nightmares – Sleep disturbances Differentiated Approach to Targeting PTSD: Addressing the Underlying Learning & Memory Dysfunction October 20, 2020 4 CURRENT APPROACHES Target symptoms OUR APPROACH Targets underl

  5. Slide 5: PTSD Symptoms and Diagnosis

    PTSD Symptoms and Diagnosis Characterized by Four Core Symptom Clusters Captured in the CAPS - 5 October 20, 2020 5 Along with these symptom clusters, a diagnosis of PTSD typically requires: • Symptoms for ≥ 1 month • Symptoms cause impairment in important areas of function Arousal & Reactivity • Ju

  6. Slide 6: Study Design, Subject Disposition, and Baseline Characteristics

    Study Design, Subject Disposition, and Baseline Characteristics October 20, 2020 6

  7. Slide 7: First-in-Patient Exploratory Phase 2 Study in PTSD

    STUDY OBJECTIVE Inform future development with regard to: First - in - Patient Exploratory Phase 2 Study of NYX - 783 in PTSD Important First Step in Evaluating the Efficacy of a Novel Mechanism 7 PHASE 1 PRECLINICAL PHASE 2 (FIRST - IN - PATIENT) Patient inclusion/exclusion criteria Endpoints Antic

  8. Slide 8: Phase 2 PTSD Study Design

    Phase 2 PTSD Study Design Pre - Specified Primary Objective: To assess efficacy of NYX - 783 in a PTSD population using CAPS - 5 total score and CAPS - 5 symptom cluster scores October 20, 2020 8 Placebo non - responders SCREENING ( 2 – 4 WEEKS) STAGE 1 (4 WEEKS) STAGE 2 (4 WEEKS) Diagnosis of PTSD

  9. Slide 9: Baseline Demographics

    Baseline Demographics Stage 1 Stage 2 Demographic Placebo (n=103) 10 mg NYX - 783 (n=24) 50 mg NYX - 783 (n=26) Total (n=153) Placebo Only (n=38) Placebo Stage 2 (n=38) 10 mg NYX - 783 (n=22) 50 mg NYX - 783 (n=26) Total (n=124) Age Mean 40.8 43.4 43.8 41.7 43.6 44.7 37.9 39.8 42.1 Gender, n (%) Mal

  10. Slide 10: Baseline Clinical Characteristics – ITT Primary Efficacy Population

    Baseline clinical characteristics are consistent with a moderate to severe PTSD patient population Baseline Clinical Characteristics – ITT Primary Efficacy Population Stage 1 Stage 2 (PBO Non - Responders) Demographic Placebo (n=103) 10 mg NYX - 783 (n=24) 50 mg NYX - 783 (n=26) Total (n=153) Placeb

  11. Slide 11: Efficacy Data

    Efficacy Data October 20, 2020 11

  12. Slide 12: Primary Objectives: CAPS-5 Arousal and Reactivity Score

    Clinically meaningful and statistically significant improvement on CAPS - 5 Arousal and Reactivity Score for 10mg, 50mg, and pooled dose groups Effect is concordant with fear extinction mechanism of NYX - 783 Significant improvement on Arousal and Reactivity symptom domain largely drove overall tren

  13. Slide 13: Primary Objectives: CAPS-5 Negative Cognitions and Mood Score

    P - values versus PBO 10mg 50mg Pooled P - values versus PBO 10mg 50mg Pooled Stage 1 NS 0.049 NS Stage 2 NS NS NS Stage 1 + Stage 2 (primary analysis) NS 0.138 NS Trend to significance in combined Stage 1+2 analysis for 50mg dose Statistically significant improvement in Negative Cognitions and Mood

  14. Slide 14: Primary Objectives: CAPS-5 Total Score

    Trend to significance in combined Stage 1+2 analysis for 50mg dose Robust and clinically meaningful reduction in CAPS - 5 Total Score from baseline during Stage 1 for 50mg dose – trend to significance despite strong placebo effect Reduction in CAPS - 5 Total Score during Stage 2 for 10mg and 50mg St

  15. Slide 15: CAPS-5 Total Score – Responder Analysis

    44% 26% 45% 30% 78% 50% ≥30% ≥50% Improvement from Baseline on CAPS - 5 Total Score Proportion of Patients Achieving Key Response Thresholds @ Week 4 Placebo (n=85) 10mg NYX-783 (n=20) 50mg NYX-783 (n=18) p=0.008 vs. PBO p=0.044 vs. PBO Analysis inclusive of ITT patients in with CAPS - 5 Total Score

  16. Slide 16: Additional Pre-Specified Endpoints: HADS-Anxiety

    P - values versus PBO 10mg 50mg Pooled P - values versus PBO 10mg 50mg Pooled Stage 1 0.024 0.018 0.004 Stage 2 0.067 NS NS Stage 1 + Stage 2 (primary analysis) 0.045 0.166 0.056 Strong effect on HADS - Anxiety scale – statistically significant for 10mg and pooled doses, trending for 50mg HADS - Anx

  17. Slide 17: Additional Pre-Specified Endpoints: PCL-5 (Patient Reported)

    P - values versus PBO 10mg 50mg Pooled P - values versus PBO 10mg 50mg Pooled Stage 1 NS 0.0987 NS Stage 2 0.138 NS NS Stage 1 + Stage 2 (primary analysis) NS 0.170 0.180 PCL - 5 is a patient response endpoint with symptom questions identical to CAPS - 5 Trend to significance for 50mg and pooled dos

  18. Slide 18: Tolerability and Adverse Event Data

    Tolerability and Adverse Event Data October 20, 2020 18

  19. Slide 19: Favorable Tolerability and Adverse Event Profile Observed

    Favorable Tolerability and Adverse Event Profile Observed Safety Population 19 October 20, 2020 Treatment Emergent Adverse Events (TEAE) Placebo Only (N=102) n (%) NYX - 783 10 mg (N=24) n (%) NYX - 783 50 mg (N=26) n (%) Total (N=152) n (%) Placebo Only (N=38) n (%) Placebo Stage 2 (N=36) n (%) NYX

  20. Slide 20: Other Adverse Event and Tolerability Observations

    No fatal adverse events No life - threatening adverse events No drug - related serious adverse events – 3 reports of suicidal ideation in the study o 2 on placebo o 1 on NYX - 783 – deemed by investigator to be unrelated to study drug No drug - related severe adverse events No signal of clinically m

  21. Slide 21: Clinician's Perspective: PTSD

    Murray Stein, MD, MPH Distinguished Professor of Psychiatry and Public Health University of California San Diego 21 Clinician’s Perspective: PTSD Staff Psychiatrist at the VA San Diego Healthcare System October 20, 2020 DSM - 5 Anxiety, Obsessive - Compulsive Spectrum, Posttraumatic, and Dissociativ

  22. Slide 22: Advancing a Leading Pipeline of CNS Therapies

    Approximate cash balance of $116 mm as of June 30, 2020, is expected to provide operational runway into 2022 INDICATION PRECLINICAL/ IND ENABLING PHASE 1 PHASE 2 PHASE 3 REGISTRATION/ COMMERCIAL CHRONIC PAIN FRANCHISE NYX - 2925 Fibromyalgia Painful Diabetic Peripheral Neuropathy PSYCHIATRY FRANCHIS

  23. Slide 23: Q&A

    Q&A October 20, 2020 23

  24. Slide 24: Summary of Top-line Results

    Robust, statistically significant, clinically meaningful, mechanistically relevant effects observed on numerous efficacy endpoints with only 4 weeks of treatment Clear dose response: 50mg dose demonstrated better effect than 10mg dose Majority of patients in the 50mg group demonstrated clinically me

Aptinyx — Technical Presentation (October 2020) on 6ix